XBiotech (XBIT) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
XBiotech (XBIT) has outperformed Zhengye Biotechnology (ZYBT) over the past year, losing 14.9% versus a loss of 47.4%. Zhengye Biotechnology is the larger company by market cap ($66.3 million vs $64.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | XBIT | ZYBT |
|---|---|---|
| Share price | $2.12 | $1.40 |
| Market cap | $64.63M | $66.35M |
| 1-day change | -1.85% | -6.67% |
| YTD return | -11.30% | +21.74% |
| 1-year return | -14.86% | -47.37% |
| 5-year return | -84.94% | — |
| Forward P/E | 16.31 | — |
| EPS (TTM) | $-1.48 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $16.64M |
| Revenue growth (YoY) | — | -34.83% |
| Net income (latest FY) | $-45.54M | $-9.98M |
| Gross margin | — | 20.51% |
| Operating margin | — | -60.60% |
| Net margin | — | -59.99% |
| 52-week high | $3.44 | $8.01 |
| 52-week low | $2.09 | $0.616 |
| Distance from 52-week high | -38.37% | -82.52% |
| Average volume | 42.87K | 5.64M |
| Shares outstanding | 30.49M | 47.39M |
| Employees | 87 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XBIT has outperformed ZYBT by 32.5 percentage points over the past year.
About XBiotech
XBIT stock →XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
XBIT vs ZYBT FAQ
Which is bigger, XBiotech or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $66.35M compared with $64.63M for XBiotech (XBIT).
Which stock has performed better over the past year, XBIT or ZYBT?
XBIT returned -14.86% over the past 12 months, compared with -47.37% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are XBiotech and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.